



Patent Docket P1101R2D1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Camellia W. Adams et al. Serial No.: 10/052798 Filed: November 2, 2001 For: APO-2 RECEPTOR	Group Art Unit: 1646 Examiner: to be assigned <div style="border: 1px solid black; padding: 5px;"><p style="text-align: center;">CERTIFICATE OF HAND DELIVERY</p><p>I hereby certify that this correspondence is being hand delivered in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on <u>3/31</u>, 2003.</p><p style="text-align: right;"><i>Reggie Mitchell</i></p></div>
---	--

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

Applicants submit herewith patents, publications or other information (attached hereto and listed on the attached revised Form PTO-1449) of which they are aware, which they believe may be material to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56.

This Information Disclosure Statement is filed in accordance with the provisions of:

☒ **37 CFR §1.97(b)**

- within three months of the filing date of the application other than a continued prosecution application under 37 CFR §1.53(d); or
- within three months of the date of entry of the national stage of a PCT application as set forth in 37 CFR §1.491, or
- before the mailing of the first Office action on the merits; or
- before the mailing of the first Office action after the filing of a request for a continued examination under 37 CFR §1.114.

☐ **37 CFR §1.97(c)**

- by the applicant after the period specified in 37 CFR §1.97(b), but prior to the mailing date of any of a final action under 37 CFR §1.113, or a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application, and is accompanied by either the fee set forth in 37 CFR §1.17(p) or a statement as specified in 37 CFR §1.97(e), as checked below.

☐ **37 CFR §1.97(d)**

- after the period specified in CFR §1.97(c), and is accompanied by the fee set forth in 37 CFR §1.17(p) and a statement as specified in 37 CFR §1.97(e), as checked below.

Serial No.: 10/052798
Filed: November 2, 2001

Page 2

[If either of boxes 37 CFR §1.97(c) or 37 CFR §1.97(d) is checked above, the following statement under 37 CFR §1.97(e) may need to be completed.]

- ☐ **37 CFR §1.97(e)** Each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.
- ☐ **37 CFR §1.704(d)** Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and the communication was not received by any individual designated in §1.56(c) more than thirty days prior to the filing of this information disclosure statement. Therefore, in accordance with the provisions of 37 CFR §1.704(d), the filing of this information disclosure statement will not be considered a failure to engage in reasonable efforts to conclude prosecution under 37 CFR §1.704.
- ☐ The U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p). Any deficiency or overpayment should be charged or credited to this deposit account.

A list of the patents or publications is set forth on the attached revised Form PTO-1449 (Modified).

A copy of the items on PTO-1449 is supplied herewith.

A concise explanation of relevance of the items listed on PTO-1449 is:

☒ not given

☐ given for each listed item

☐ given for only non-English language listed item(s) [Required]

☐ in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR §1.97(g), the filing of this information disclosure statement shall not be construed as a representation that a search has been made.

In accordance with 37 CFR §1.97(h), the filing of this information disclosure statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b).

Serial No.: 10/052798
Filed: November 2, 2001

Page 3

In the event that the Office determines a fee to be due where none is specifically authorized in this paper, the U.S. Patent and Trademark Office is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$180.00 to cover the cost of this Information Disclosure Statement under 37 CFR §1.17(p).

Respectfully submitted,

GENENTECH, INC.

Date: February 28, 2003

By: Diane L. Marschang

Diane L. Marschang


Reg. No. 35,600

Telephone No. (650) 225-5416



09157

PATENT TRADEMARK OFFICE
#121651



Sheet 1 of 2

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P1101R2D1Serial No.
10/052,798

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant
Adams et al.Filing Date
02 Nov 2001Group
To Be Assigned

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
	1	08/799,861					13.02.97
	2	08/820,364		Gearing			12.03.97
	3	08/843,651		Holtzman			16.04.97
	4	08/843,652		Holtzman			16.04.97
	5	08/853,684					09.05.97
	6	08/869,852					04.06.97
	7	08/916,625					22.08.97
	8	09/042,583					17.03.98
	9	09/565,009					04.05.00
	10	09/712,726		Gearing			14.11.00
	11	2002/0048566	25.04.02	El-Deiry et al.			13.09.01
	12	2002/0048785	25.04.02	Holtzman			
	13	2002/0072091	13.06.02	Ni et al.			
	14	2002/0098550	25.07.02	Ni et al.			
	15	2002/0160446	31.10.02	Holtzman			
	16	4,855,235	08.08.89	Takahashi et al.			
	17	5,153,118	06.10.92	Wright, Jr. et al.			
	18	5,158,885	27.10.92	Bradstock et al.			
	19	5,763,223	09.06.98	Wiley et al.			
	20	6,313,269	06.11.01	Deen et al.			
	21	6,455,262	24.09.02	Cox et al.			
	22	60/040,846					17.03.97
	23	60/041,230					14.03.97
	24	60/054,021					29.07.97
	25	60/132,498					04.05.99
	26	60/133,238					07.05.99
	27	60/148,939					13.08.99

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes No
	28	WO 00/77191		PCT			
	29	WO 02/053727	11.07.02	PCT			

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

	30	Chapman, "A Region of the 75 kDa neurotrophin receptor homologous to the death domains of TNFR-I and Fas" <u>B.S. Chapman/FEBS Letters</u> 374:216-220 (1995)
	31	Chuntharapai and Kim, "Generation of Monoclonal Antibodies to Chemokine Receptors" <u>Methods in Enzymology</u> 288:15-27 (1997)

Examiner

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



In re Application of: Adams et al.

Serial No.: 10/052,798

Filed On: Nov. 2, 2001

Hand Delivered On: 3/31 2003

Docket No.: P1101R2D1

By: Diane L. Marschang

Reg. No.: 35,600

The following has been received in the U.S. Patent Office on the date stamped:

- ☒ Communication/Transmittal
- ☒ Supplemental Information Disclosure Statement
- ☒ Form 1449 with 42 References
- ☒ Certificate of Hand Delivery

RECEIVED
TECH CENTER 1600/2900
03 MAR - 3 PM 12:10



Patent Docket P1101R2D1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Camellia W. Adams et al. Serial No.: 10/052798 Filed: November 2, 2001 For: APO-2 RECEPTOR	Group Art Unit: 1646 Examiner: To Be Assigned <div style="border: 1px solid black; padding: 5px;"><p style="text-align: center;">CERTIFICATE OF HAND DELIVERY</p><p>I hereby certify that this correspondence is being hand delivered in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on</p><p style="text-align: center;">3/31, 2003 <i>Reggie Mitchell</i></p></div>
---	---

TRANSMITTAL LETTER

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

Transmitted herewith are the following documents:

1. Supplemental Information Disclosure Statement;
2. Form PTO-1449 with 42 References;
3. Return postcard.

In the event any additional fees are due in connection with the filing of these documents, the Commissioner is authorized to charge such fees to our Deposit Account No. 07-0630.

Respectfully submitted,

GENENTECH, INC.

Date: February 28, 2003

By: *Diane L. Marschang*
Diane L. Marschang
Reg. No. 35,600
Telephone No. (650) 225-5416



09157

PATENT TRADEMARK OFFICE
#129007